pharmaphorum

JUNE 8, 2022

The passport means that LentiGlobin will be reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new innovative licensing and access pathway (ILAP) introduced in 2020, which reduces the review time for a new medicine to 150 days.

Gene Silencing 52

Gene Silencing Drugs Medicine Regulation 52

pharmaphorum

JULY 28, 2022

Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and cardiovascular disease.

Biobanking 52

Biobanking Gene Gene Silencing Drugs 52

pharmaphorum

DECEMBER 23, 2020

Biogen and Denali will co-market the lead LRRK2 product in the US and China, and Biogen will commercialise in all other markets. NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause. Rare disease progress.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

Delveinsight

AUGUST 6, 2020

Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. They help in preventing confrontational changes and dissociation of protein, and not halt the production of the protein. Gene-silencing Therapies. Liver Transplantation.

Protein 52

Protein Gene Silencing Marketing Gene 52